Dihydropyridine Calcium Channel Antagonists
Nifedipine, Amlodipine
- User: Male
- Hormonal: Non-Hormonal
-
Delivery type:
- Not Yet Determined
-
Intended Duration:
- Not Yet Determined
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Rawalpindi Medical University, University of Basra, Babcock University
Details
- API: Nifedipine
- Target: Not Yet Determined
-
Mechanism of Action:
- Reduced Sperm Production
- Inactive Materials: Not Yet Determined
- Regimen: Not Yet Determined
- MPT: Not Potential MPT
- Promising Attributes: Nifedipine is believed to cause reversible infertility in male users. The drug has regulatory approval as a blood pressure medication, which may be beneficial for clinical evaluation and regulatory approval as a contraceptive.
Product Status
No evidence of development after 2019
History
1993: Calcium channel blocker nifedipine evaluated in vitro for affect on sperm viability and motility. Found to have significant impact on motility and structure of sperm. Complementary results reported in 1994 Journal of NIH Research
2009: Nifedipine found to have reversable antifertility effect on rats
2019: Nifedipine found to significantly decrease serum testosterone and serum LH in rats